Register now
Register to receive full, unrestricted access to our resources, regular updates and partnership opportunities
Collaboration
Collaboration sits at the heart of how Novartis UK partners with the NHS.
Our projects focus on shared goals:
Image
Supporting service
improvement
Image
Enabling innovation
Image
Reducing unwarranted
variation
Image
Helping teams deliver more efficient and effective care
Every collaboration aims to deliver a triple win:
- Better outcomes for patients, supported through efficient pathways and earlier, more consistent access to appropriate care.
- Tangible gains for NHS organisations, including released capacity, smoother workflows, improved monitoring, or more equitable access in underserved communities.
- Clear value for Novartis UK, through working transparently in areas where we have deep expertise, including cancer, cardiovascular disease, neuroscience, haematology and dermatology, ensuring that service strengthening also supports appropriate access to innovative medicines (in line with national and/or local guidelines).
Image
Image
Explore our interactive map of partnership working across the UK
Each initiative reflects locally defined priorities, backed by NHS leadership and governed by full ABPI compliance. These projects span a range of focus areas, including access and engagement in underserved communities, earlier patient identification, pathway re-design, workforce optimisation, digital optimisation, service sustainability, and care delivery closer to home, across a number of therapy areas.
Image
Get in touch
to learn more about our collaborations
“They are more than joint initiatives. They are strategic alliances aimed at improving patient outcomes and relieving system pressures by combining Novartis expertise, resources and innovation with the clinical excellence of the NHS.”
Jeremy
Dixon,
Value & Access Marketing Director, Novartis UK
By sharing these projects openly, we aim to support cross-system learning and help spread proven approaches that align with wider national objectives, including the Fit for the Future: 10 Year Health Plan for England1 , Core20PLUS52, and NHS programs aimed at narrowing health inequalities.
Image
Project scoping
Novartis, healthcare organisations (HCOs) and others jointly:
|
|
|
Key questions at this stage:
|
|
Image
Collaborative working criteria check
Both parties assess the proposal against the ABPI Collaborative Working criteria to ensure eligibility and compliance from the outset.
To ensure Novartis is positioned to provide meaningful expertise and support, proposed projects should align with one of the following therapy areas:
|
|
|
Image
Stakeholder alignment
Alignment is confirmed across objectives, governance and compliance, with approval in principle and high-level timelines agreed.
Early and proactive engagement is critical. Before progressing, we must ensure:
|
|
Where recruitment forms part of the project:
|
|
Early alignment prevents delays and ensures shared ownership.
Image
Draft project initiation document (PID)
A draft PID is co-created by Novartis, the HCO and others. This document defines:
|
|
|
Opportunities to share learning, such as case studies, panel sessions or award submissions, may also be considered where appropriate.
Image
Governance and approvals
The PID undergoes robust internal review from all parties involved, including:
|
|
Formal approval must be secured before any project activity begins.
Image
Finalise PID
All feedback is incorporated and final sign-off confirmed by both parties.
Image
Sign agreement and publish summary
The Collaborative Working Agreement is signed (different to the PID). An executive summary is published by both parties in line with ABPI transparency requirements3 before project initiation.
Any associated funding from Novartis will only be released if the agreement is signed by all parties.
Image
Project kick-off
Where required, supplier registration is completed. A formal kick-off meeting confirms:
|
|
|
Image
Delivery and monitoring
The project is delivered in accordance with the agreement, supported by:
|
|
Governance remains active throughout.
Image
Completion and outcomes
Within six months of completion, all parties should publish online an outcomes summary to support transparency, shared learning and future scalability.3
Image
Get in touch
to learn more about our collaborations
Discover more about
Explore our partnerships across the UK
Discover how partnership-led change between the pharmaceutical industry and the NHS is shaping the future of healthcare.
References:
NHS England. Fit For the Future: 10 Year Health Plan for England. Available at: https://assets.publishing.service.gov.uk/media/6888a0b1a11f859994409147/fit-for-the-future-10-year-health-plan-for-england.pdf [Last accessed: June 2026]
NHS England. Core20PLUS5 (adults) – an approach to reducing healthcare inequalities. Available at: https://www.england.nhs.uk/about/equality/equality-hub/national-healthcare-inequalities-improvement-programme/core20plus5/ [Last accessed: June 2026]
PMCPA. ABPI code of practice for the pharmaceutical industry. Available from: https://www.pmcpa.org.uk/media/r0anf5ya/2024-abpi-code.pdf [Last accessed June 2026]
UK | June 2026 | FA-11624103 Fictional patient and healthcare professional images.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
